Journal articles: 'Anti asthma drug'

1

Rottier, Bart L., and Eric J. Duiverman. "Anti-inflammatory drug therapy in asthma." Paediatric Respiratory Reviews 10, no. 4 (December 2009): 214–19. http://dx.doi.org/10.1016/j.prrv.2009.06.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Snell, N. J. C. "Drug interactions with anti-asthma medication." Respiratory Medicine 88, no. 2 (February 1994): 83–88. http://dx.doi.org/10.1016/0954-6111(94)90019-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Meszaros, A., V. Zoltan, and E. Galik. "PRS14: ASTHMA AND ANTI-ASTHMA DRUG USE IN HUNGARY." Value in Health 3, no. 5 (September 2000): 331–32. http://dx.doi.org/10.1016/s1098-3015(11)70710-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Calhoun, W. "Anti-leukotrienes for asthma." Current Opinion in Pharmacology 1, no. 3 (June 1, 2001): 230–34. http://dx.doi.org/10.1016/s1471-4892(01)00041-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Knyazheskaya, N. P., A. S. Belevskiy, and E. V. Safoshkina. "Anti-IgE therapy for severe atopic asthma." Russian Journal of Allergy 16, no. 1 (February 15, 2019): 71–78. http://dx.doi.org/10.36691/rja30.

Full text

Abstract:

The first targeted drug that is used for patients with uncontrolled moderate and severe atopic asthma (BA) was anti-IgE drug omalizumab (Xolar®). This drug is prescribed to patients with moderate to severe atopic BA, which is not controlled by baseline therapy corresponding to stage 4 (level of evidence A). Clinical studies have convincingly demonstrated that in patients with severe asthma requiring treatment with high doses of inhaled corticosteroids or oral glucocorticosteroids, treatment with Xolar® reduces the frequency of exacerbations of BA, reduces the severity of asthma and allows for steroid-dependent BA to cancel or significantly reduce the dose of systemic corticosteroids. In addition, the anti-inflammatory effect of the drug has been proven. Studies in recent years provide more and more data on the positive impact of omalizumab on the remodeling of the respiratory tract.

APA, Harvard, Vancouver, ISO, and other styles

6

Vakily, Majid, Reza Mehvar, and Dion Brocks. "Stereoselective Pharmacokinetics and Pharmacodynamics of Anti-Asthma Agents." Annals of Pharmacotherapy 36, no. 4 (April 2002): 693–701. http://dx.doi.org/10.1345/aph.1a248.

Full text

Abstract:

OBJECTIVE: To review the previously published studies on pharmacokinetics and pharmacodynamics of chiral drugs used in the treatment of asthma. DATA SOURCES: Primary and review articles were identified with a MEDLINE search (1980–May 2001) and through secondary sources. STUDY SELECTION AND DATA EXTRACTION: All English-language studies and reviews obtained from the MEDLINE search pertaining to stereoselective pharmacokinetics and pharmacodynamics of chiral anti-asthma drugs were assessed. DATA SYNTHESIS: Several anti-asthma drugs (e.g., β2-adrenergic agonists, leukotriene modifiers) are chiral and marketed as racemates, which consist of equal proportions of 2 enantiomers. Significant stereoselectivity has also been reported in pharmacodynamics and pharmacokinetics of the β2-agonists. The enantiomers of β2-agonists in the R configuration are primarily responsible for the bronchodilating effects of the racemate. The plasma concentrations of the enantiomers of anti-asthma drugs may differ as a reflection of stereoselectivity in clearance, volume of distribution, and route of administration. CONCLUSIONS: Stereoselectivity in the pharmacokinetics of anti-asthma drugs may complicate the relationship between dose and/or plasma concentration of racemic drug versus effect relationship. An appreciation of the stereoselective pharmacokinetics and pharmacodynamics of chiral anti-asthma drugs may optimize the use of these agents in asthmatic patients.

APA, Harvard, Vancouver, ISO, and other styles

7

Trivedi, Nitant, Hemangini R. Acharya, Manish J. Barvaliya, and C. B. Tripathi. "Prescribing pattern in patients of asthma visiting outpatient departments of a tertiary care hospital: a cross-sectional, observational study." International Journal of Basic & Clinical Pharmacology 6, no. 3 (February 24, 2017): 587. http://dx.doi.org/10.18203/2319-2003.ijbcp20170818.

Full text

Abstract:

Background: Objective of the study was to evaluate the prescribing pattern in patients of asthma visiting outpatient departments.Methods: Collected prescriptions were analyzed for demographic variables, proportions of various comorbid conditions, average number of drugs per prescription, average number of anti-asthmatic drugs per prescription, proportion of prescription with antibiotics, fixed dose combinations, and generic/brand names, proportion of formulations utilized, proportion of concomitant medications and possible drug interactions, average cost per prescription, average cost of antiasthmatic drugs per prescription, proportion of irrational prescription and adverse drug reactions.Results: Total 139 prescriptions were evaluated. Deriphyllin was the most commonly prescribed anti-asthmatic drug followed by beta agonist- steroid combination. Majority drugs were prescribed by inhalational route. Deriphyllin, and dexamethasone were prescribed by oral route and salbutamol was by both oral and inhalational route of administration. Antibiotics were prescribed to 24 patients. Possible drug interaction with deriphyllin was found in 15 prescriptions. Average cost per prescription was Rs. 193.4 (95%CI: 171.6-215.3).Conclusions: Prescribing pattern of asthma in our hospital shows more use of anti-asthmatic drugs. Standard treatment guideline should be followed. Role of methylxanthine in long term management of asthma should be justified.

APA, Harvard, Vancouver, ISO, and other styles

8

S., Narendra Babu, Vinoth Kumar C., and Nandini R. "Comparative study of adverse drug reaction pattern of two anti-asthma groups of drugs in a tertiary care hospital." International Journal of Basic & Clinical Pharmacology 8, no. 4 (March 23, 2019): 788. http://dx.doi.org/10.18203/2319-2003.ijbcp20191118.

Full text

Abstract:

Background: Bronchial Asthma is one of the worldwide health problems associated with increased morbidity and also mortality. Bronchial Asthma is a disease of airways that is characterized by increased responsiveness of the trachea-bronchial tree. Anti asthmatic drugs are associated with adverse effects which can affect the compliance and course of treatment. Monitoring adverse drug reactions in asthma will play a vital role in alerting physicians about the possibility and circumstances of such events, thereby protecting the user population from avoidable harm.Methods: The study was conducted in 500 bronchial asthma patients (250 patients in Beta 2 agonist group (Salbutamol) and 250 patients in Methylxanthine group (Deriphyllin) who fulfilled the study criteria and were observed for three months at Madras Medical College and Rajiv Gandhi Government General Hospital, Chennai. Their prescriptions were collected and analysed. Adverse drug reactions(ADRs) in each group were collected and evaluated. The causality assessment was done by WHO-UMC assessment scale and severity by using Modified Hartwig-Seigel severity assessment scale.Results: Total 38% of patients taking anti-asthma drugs were encountered adverse drug reactions and were more common in elderly females (61 to 70 years). Adverse Drug Reactions were more common in Methylxanthine group (48%) compared to Beta 2 agonist group (28%). Headache (38%) was the commonest ADR in Methylxanthine group and Tremors (31%) in Beta 2 agonist group. Most of ADRs were mild (95 %), manageable and comes under possible (60 %) category of WHO causality assessment scale.Conclusions: Treatment of Bronchial Asthma is mainly based on Beta 2 agonist and Methylxanthine group. So, occurrence of ADR is much common. Our study offers a representative idea of the ADR profile of anti asthmatic drugs. Constant vigil in detecting ADRs and subsequent dose adjustments can make therapy with anti asthmatic drugs safer and more effective. This, in turn, will improve compliance.

APA, Harvard, Vancouver, ISO, and other styles

9

Du, Chunhua, Qi Zhang, Lina Wang, Mei Wang, Jinfeng Li, and Qian Zhao. "Effect of Montelukast Sodium and Graphene Oxide Nanomaterials on Mouse Asthma Model." Journal of Nanoscience and Nanotechnology 21, no. 2 (February 1, 2021): 1161–68. http://dx.doi.org/10.1166/jnn.2021.18705.

Full text

Abstract:

Because some asthma patients have different types of inflammatory cells in their bodies, they cannot get relief with traditional drugs. However, the nano drug delivery system can realize efficient drug delivery, inflammatory cells and intracellular targeting, and the apoptosis of inflammatory cells. This article aims to comprehensively evaluate the effects of montelukast sodium combined with graphene oxide nanomaterials on improving the clinical symptoms and airway inflammation of children with bronchial asthma, with a view to further improving the clinical treatment of children with bronchial asthma. The results show that montelukast sodium can improve lung function in patients with asthma, and also has important effects such as anti-inflammatory and regulating immune function. After exposure to graphene oxide, the level of oxidative stress in mice increased with brightness and humidity, demonstrating the role of T oxidative stress in the development of asthma. In addition, nanocarriers assist co-loaded drugs to deepen and enrich the pulmonary inflammation site, further achieving effective mitochondrial targeted drug delivery, thereby enhancing the inhibitory effect of anti-apoptotic proteins, leading to inflammatory cell apoptosis.

APA, Harvard, Vancouver, ISO, and other styles

10

HOLDCROFT, CAROL. "Nedocromil: A New Anti-inflammatory Drug for Asthma." Nurse Practitioner 19, no. 3 (March 1994): 7–8. http://dx.doi.org/10.1097/00006205-199403000-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Seidel, Petra, and Michael Roth. "Anti-Inflammatory Dimethylfumarate: A Potential New Therapy for Asthma?" Mediators of Inflammation 2013 (2013): 1–10. http://dx.doi.org/10.1155/2013/875403.

Full text

Abstract:

Asthma is a chronic inflammatory disease of the airways, which results from the deregulated interaction of inflammatory cells and tissue forming cells. Beside the derangement of the epithelial cell layer, the most prominent tissue pathology of the asthmatic lung is the hypertrophy and hyperplasia of the airway smooth muscle cell (ASMC) bundles, which actively contributes to airway inflammation and remodeling. ASMCs of asthma patients secrete proinflammatory chemokines CXCL10, CCL11, and RANTES which attract immune cells into the airways and may thereby initiate inflammation. None of the available asthma drugs cures the disease—only symptoms are controlled. Dimethylfumarate (DMF) is used as an anti-inflammatory drug in psoriasis and showed promising results in phase III clinical studies in multiple sclerosis patients. In regard to asthma therapy, DMF has been anecdotally reported to reduce asthma symptoms in patients with psoriasis and asthma. Here we discuss the potential use of DMF as a novel therapy in asthma on the basis ofin vitrostudies of its inhibitory effect on ASMC proliferation and cytokine secretion in ASMCs.

APA, Harvard, Vancouver, ISO, and other styles

12

Gordon, Bruce R. "Asthma: An Important Disease to Otolaryngologists — Part II: Asthma Management Strategy." Ear, Nose & Throat Journal 75, no. 3 (March 1996): 136–42. http://dx.doi.org/10.1177/014556139607500308.

Full text

Abstract:

Asthma is a chronic inflammatory disease of the lower respiratory tract which is triggered by exposure to allergens or other airway irritants, and is commonly encountered in otolaryngologic practice. This three-part review is designed to assist otolaryngologists in effectively managing their asthmatic patients. In Part I, current information on the pathophysiology and increasing prevalence of asthma, its clinical variability, the assessment of asthma severity and methods for diagnosis of asthma were summarized. Part 11 discusses a tripartite strategy for asthma management, based on environmental controls, the use of anti-inflammatory therapies and patient education. In addition, pharmacologic treatments which are not primarily anti-inflammatory are reviewed in detail. The uses, effectiveness, side effects and suitability for drug combination therapy for mucolytic, anticholinergic, antihistamine, theophylline and beta agonist drugs are compared, and the disadvantages of beta antagonists are summarized. Part III concludes with an overview of antiinflammatory therapies for asthma control.

APA, Harvard, Vancouver, ISO, and other styles

13

Navinés-Ferrer, Arnau, Eva Serrano-Candelas, Gustavo-J. Molina-Molina, and Margarita Martín. "IgE-Related Chronic Diseases and Anti-IgE-Based Treatments." Journal of Immunology Research 2016 (2016): 1–12. http://dx.doi.org/10.1155/2016/8163803.

Full text

Abstract:

IgE is an immunoglobulin that plays a central role in acute allergic reactions and chronic inflammatory allergic diseases. The development of a drug able to neutralize this antibody represents a breakthrough in the treatment of inflammatory pathologies with a probable allergic basis. This review focuses on IgE-related chronic diseases, such as allergic asthma and chronic urticaria (CU), and on the role of the anti-IgE monoclonal antibody, omalizumab, in their treatment. We also assess the off-label use of omalizumab for other pathologies associated with IgE and report the latest findings concerning this drug and other new related drugs. To date, omalizumab has only been approved for severe allergic asthma and unresponsive chronic urticaria treatments. In allergic asthma, omalizumab has demonstrated its efficacy in reducing the dose of inhaled corticosteroids required by patients, decreasing the number of asthma exacerbations, and limiting the effect on airway remodeling. In CU, omalizumab treatment rapidly improves symptoms and in some cases achieves complete disease remission. In systemic mastocytosis, omalizumab also improves symptoms and its prophylactic use to prevent anaphylactic reactions has also been discussed. In other pathologies such as atopic dermatitis, food allergy, allergic rhinitis, nasal polyposis, and keratoconjunctivitis, omalizumab significantly improves clinical manifestations. Omalizumab acts in two ways: by sequestering free IgE and by accelerating the dissociation of the IgE-Fcεreceptor I complex.

APA, Harvard, Vancouver, ISO, and other styles

14

Booth, Andrew. "Inhaled therapy for asthma." Journal of Prescribing Practice 2, no. 6 (June 2, 2020): 300–308. http://dx.doi.org/10.12968/jprp.2020.2.6.300.

Full text

Abstract:

Inhaled therapy is key to the successful treatment of asthma. National guidelines provide us with the aim of asthma management, which is to maintain control of the disease. The correct combination of drug and device can be individually tailored to the patient. Drugs consist of bronchodilators and anti-inflammatories. Devices consist of aerosol inhalers, also known as pressurised metered dose inhalers, and dry powder inhalers. Both the drug and the device need to be prescribed if the treatment is to be clinically effective. A combination of inhaled steroid with long-acting B2 agonist is one of the most clinically effective ways of delivering asthma treatment. This can be prescribed either as a fixed daily dose with a concomitant short-acting B2 agonist as a reliever, or as maintenance and reliever therapy, which has been shown to improve asthma control and reduce exacerbations.

APA, Harvard, Vancouver, ISO, and other styles

15

Kupczyk, Maciej, Barbro Dahlén, and Sven-Erik Dahlén. "Which anti-inflammatory drug should we use in asthma?" Polish Archives of Internal Medicine 121, no. 12 (December 1, 2011): 455–60. http://dx.doi.org/10.20452/pamw.1115.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Adhaulia, Garima, Divya Singh, Suryakant ., Ajay Verma, Arpita Singh, Rajendra Nath, Amod K. Sachan, and Rakesh K. Dixit. "Study of prescribing pattern of drugs used in the treatment of bronchial asthma at tertiary care hospital of northern India." International Journal of Basic & Clinical Pharmacology 9, no. 2 (January 24, 2020): 322. http://dx.doi.org/10.18203/2319-2003.ijbcp20200184.

Full text

Abstract:

Background: Asthma is a chronic inflammatory disease requiring long term treatment. For an effective control of asthma symptoms background knowledge of the prescribing pattern of anti-asthmatic drugs is a must.Methods: A prospective, observational study was conducted in the Department of Respiratory Medicine OPD, King George's Medical University, Lucknow. 114 patients of asthma were recruited for the study. A case report form was filled from patient’s prescription containing the demographic details of the patients, presenting complaints, investigations and drugs prescribed along with their dose, duration, frequency, route of administration.Results: 114 patients’ prescriptions were assessed which showed average number of drugs per prescription - 3.22. 42.8% and 50% of the drugs were prescribed in accordance with World Health Organization model list of essential medicines and National list of essential medicines. Short acting β2 agonist (salbutamol), 61.4% was the most commonly and frequently prescribed single anti asthmatic drug. Combination of inhaled corticosteroid and long acting β2 agonist, 86.8% was the most commonly prescribed fixed dose combination anti asthmatic drug. Inhalational route (75%) was the most preferred one over oral route (25%).Conclusions: Asthma being a chronic disease requires prolonged treatment which imposes economic burden on the patients. Judicious prescription of drugs not only improves the patient clinically but also removes the unnecessary burden. Data obtained from these studies can be used as a guide to make future decisions regarding standard prescription.

APA, Harvard, Vancouver, ISO, and other styles

17

Booth, Andrew. "Inhaled therapy for asthma." Practice Nursing 31, no. 7 (July 2, 2020): 290–99. http://dx.doi.org/10.12968/pnur.2020.31.7.290.

Full text

Abstract:

Andrew Booth explains why this is the preferred − and more successful − method when managing asthma Inhaled therapy is key to the successful treatment of asthma. National guidelines provide us with the aim of asthma management, which is to maintain control of the disease. The correct combination of drug and device can be individually tailored to the patient. Drugs consist of bronchodilators and anti-inflammatories. Devices consist of aerosol inhalers, also known as pressurised metered dose inhalers, and dry powder inhalers. Both the drug and the device need to be prescribed if the treatment is to be clinically effective. A combination of inhaled steroid with long-acting B2 agonist is one of the most clinically effective ways of delivering asthma treatment. This can be prescribed either as a fixed daily dose with a concomitant short-acting B2 agonist as a reliever, or as maintenance and reliever therapy, which has been shown to improve asthma control and reduce exacerbations.

APA, Harvard, Vancouver, ISO, and other styles

18

Zyryanov, S. K., and O. I. Butranova. "Genetically engineered drugs for treatment of bronchial asthma: recent achievements." Russian Pulmonology 28, no. 5 (December 24, 2018): 584–601. http://dx.doi.org/10.18093/0869-0189-2018-28-5-584-601.

Full text

Abstract:

Current population of patients with asthma is characterized by increasing resistance to standard pharmacotherapeutic agents such as inhaled corticosteroids, antileukotriene agents and anti-IgE antibodies. These findings were confirmed by international statistic data and indicate insufficient efficacy of the treatment. Asthma phenotyping encompassing a role of certain biomarkers for bronchial inflammation could contribute to achieving better response to treatment. Genetically engineered drugs could directly impact on mediators and modulators involved in the inflammation and bronchoconstriction. This is one of the most promising directions of the modern pharmacotherapy, particularly considering severe and difficult-to-treat asthma. A comparative analysis of efficacy and safety of currently available genetically engineered drug groups (monoclonal anti-IgE antibodies, monoclonal antibodies against interleukin (IL)-4/IL-13 and IL-5, and prostaglandin D2 receptor antagonists) was performed by the authors of this article on the basis of results of randomized controlled clinical trials (RCT). According to RCT results, omalizumab is still the leading genetically engineered drug. Moreover, evidence of efficacy and safety of novel agents has been published that allowed implementation these drugs in the routine clinical practice for treatment of severe eosinophilic asthma.

APA, Harvard, Vancouver, ISO, and other styles

19

Kniajeskaia, N. P., E. Kh Anaev, A. A. Kameleva, E. V. Safoshkina, and N. D. Kirichenko. "Targeted therapy in bronchial asthma. Benralizumab: focus on patients using systemic glucocorticosteroids." Meditsinskiy sovet = Medical Council, no. 17 (November 22, 2020): 9–16. http://dx.doi.org/10.21518/2079-701x-2020-17-9-16.

Full text

Abstract:

A severe course of bronchial asthma develops in 5–20% of patients with bronchial asthma. The use of key disease-modifying agents for the treatment of severe bronchial asthma (SBA) is not always effective due to the possible uncontrolled course of the disease and persistence of signs of eosinophilic airway inflammation. Therefore, the isolation of phenotypes/ endotypes is important for an individual approach to the treatment of such patients. This method permits to get better control over the disease and reduces the risks of exacerbations, airway remodelling and unwanted adverse reactions to the therapy particularly with systemic glucocorticosteroids. The use of biological therapy among other drugs can greatly contribute to the achievement of good control over management of patients with uncontrolled severe asthma. There are currently 5 registered immunobiological drugs in Russia that belong to the group of SBA phenotype-based treatment modalities: anti-IgE therapy, anti-IL-4/13 therapy, anti-IL-5 therapy and anti-IL5Rα therapy. Depending on the disease history, clinical features of bronchial asthma course, the presence of hypersensitivity to one of the year-round allergens and the levels of laboratory markers, the medical professional establishes the exact diagnosis indicating a disease phenotype (allergic BA, eosinophilic or non-allergic BA) and addresses an issue of an appropriate drug for a patient with BA. Benralizumab (Fazenra), a humanized monoclonal antibody, generates considerable interest. Benralizumab has a slightly different principle of action: it blocks not interleukin-5 itself, but the alpha subunit of the interleukin-5 receptor (IL-5Rα), triggers active apoptosis of eosinophils, reducing their level in sputum and blood. The results of clinical studies showed the efficacy of the drug, which resulted in the significant reduction of bronchial asthma exacerbations and a dose of systemic glucocorticosteroids.

APA, Harvard, Vancouver, ISO, and other styles

20

Lyan, Natalya Anatolievna, Maya Alekseevna Khan, Marina Anatolievna Rassulova, Irina Ivanovna Ivanova, and Irina Anatolievna Bokova. "Technologies of medical rehabilitation of children with bronchial asthma." Fizioterapevt (Physiotherapist), no. 3 (May 25, 2021): 71–82. http://dx.doi.org/10.33920/med-14-2106-08.

Full text

Abstract:

Review purpose: the presentation of modern technologies of medical rehabilitation of children with bronchial asthma. Basic provisions: Recently, the increasing significance is attached to non-drug methods of treatment of bronchial asthma owing to the high frequency of undesirable effects when using medicinal preparations. The main objectives of medical rehabilitation in bronchial asthma are normalizing respiratory function, rendering anti-inflammatory and anti-edematous effect on bronchial mucosa, normalizing the state of the central and autonomic nervous system, increasing tolerance to an exercise stress, and strengthening protective forces of an organism. Conclusion: The treatment of children with bronchial asthma with the use of non-drug technologies is applied at all stages of medical rehabilitation.

APA, Harvard, Vancouver, ISO, and other styles

21

Kikuchi, Kazuhiko, and Hajime Takizawa. "Lung Remodeling in Asthma: A New Target of Anti-Asthma Therapy." Drug Design Reviews - Online 2, no. 2 (March 1, 2005): 129–36. http://dx.doi.org/10.2174/1567269053202679.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Goverdhan, Gilla, Anumula Raghupathi Reddy, Vurimidi Himabindu, and Ghanta Mahesh Reddy. "Concise and Alternative Synthesis of Zafirlukast, an Anti-Asthma Drug." Synthetic Communications 43, no. 4 (November 8, 2012): 498–504. http://dx.doi.org/10.1080/00397911.2011.603875.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Pelaia, Corrado, Cecilia Calabrese, Alessandro Vatrella, Maria Teresa Busceti, Eugenio Garofalo, Nicola Lombardo, Rosa Terracciano, and Girolamo Pelaia. "Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma." BioMed Research International 2018 (2018): 1–9. http://dx.doi.org/10.1155/2018/4839230.

Full text

Abstract:

Asthma is a very frequent chronic airway disease that includes many different clinical phenotypes and inflammatory patterns. In particular, eosinophilic bronchial inflammation is often associated with allergic as well as nonallergic asthma. The most important cytokine involved in the induction, maintenance, and amplification of airway eosinophilia in asthma is interleukin-5 (IL-5), released by both T helper 2 (Th2) lymphocytes and group 2 innate lymphoid cells (ILC2). Hence, IL-5 and its receptor are suitable targets for selective biologic drugs which can play a key role in add-on treatment of severe eosinophilic asthma refractory to corticosteroids. Within such a context, the anti-IL-5 monoclonal antibodies mepolizumab and reslizumab have been developed and approved for biological therapy of uncontrolled eosinophilic asthma. In this regard, on the basis of several successful randomized controlled trials, the anti-IL-5 receptor benralizumab has also recently obtained the approval from US Food and Drug Administration (FDA).

APA, Harvard, Vancouver, ISO, and other styles

24

Gawali, Ujwala P., Parmeshwar B. Gholve, Salman H. Rizvi, and Prashant S. Mishra. "Prescription pattern study of antiasthmatics drugs in tertiary care centre." International Journal of Basic & Clinical Pharmacology 10, no. 4 (March 22, 2021): 429. http://dx.doi.org/10.18203/2319-2003.ijbcp20211028.

Full text

Abstract:

Background: Bronchial asthma is a social and economic healthcare burden. Drug Utilization studies can play a key role in helping the healthcare system to understand, interpret and improve the prescribing administration & use of medications.Methods: A prospective, Cross-sectional, Observational study was conducted at inpatient and outpatient Department of Medicine and Paediatrics in tertiary health care centre. As per inclusion criteria, 127 patients with asthma were interviewed, and prescription data was recorded in a pre-designed case record form from 1 October 2018 to 31 December 2018.Results: A total of 127 prescriptions were studied. It was observed that majority of the study patients were in the age group of 40-50 years, with 83 (65.5%) males and 44 (34.6%) females. Most of the patients were of Mild intermittent asthma 65 (51.18 %) followed by patients with Mild persistent asthma 31 (24.40 %). 10 different anti-asthmatics drugs were prescribed along with adjunctive medicines. Most of the patients received multiple drug therapy 98 (77.16 %). Prevalence of two drug combination was the highest 74 (58.26 %) followed by monotherapy29 (22.83 %). Most common route of drug administration was inhalational route followed by oral route. β2 agonists and corticosteroids were the most commonly prescribed combination drugs followed by methylxanthines. 103 (81.10 %) prescription contains both generic and brand drugs compared to generic names only 16 (12.59 %) and brand names only 8 (6.29 %).Conclusions: This study concluded that the present prescribing practice in asthma therapy in tertiary care centre is not sufficiently rational. Hence, it is necessary to encourage physicians to follow asthma guidelines while managing asthmatic patients.

APA, Harvard, Vancouver, ISO, and other styles

25

Majumdar, Sreyashi, Abhirupa Ghosh, and Sudipto Saha. "Modulating Interleukins and their Receptors Interactions with Small Chemicals Using In Silico Approach for Asthma." Current Topics in Medicinal Chemistry 18, no. 13 (October 4, 2018): 1123–34. http://dx.doi.org/10.2174/1568026618666180801092839.

Full text

Abstract:

Asthma is a complex, heterogeneous, airway inflammatory disorder broadly classified into atopic (IgE mediated) and non-atopic asthma. Monoclonal Antibodies (MAbs) and small chemical Protein- Protein Interaction Modulators (PPIMs) are targeted against interleukins (ILs), which play a critical role in asthma. Many MAbs are targeted against ILs and IgE. Anti IgE MAb (Omalizumab) and Anti IL- 5 MAbs (Mepolizumab, Reslizumab) have only been approved by FDA. Most of the MAbs including Tracolizumab, Lebrikizumab, Anrukinzumab (Anti IL-13 MAb), and Brodalumab (Anti IL-17 MAb) are in different phases of clinical trials. Pascolizumab (Anti IL-4 MAb), however, has failed. These MAbs are expensive and may render adverse immune response. Thus, small chemical modulators targeting ILs and their receptors (IL-Rs) are being exploited computationally and further validated experimentally. The complex ILs and IL-Rs available in PDB are best suited for these types of studies. A large number of small chemical modulators against Protein-Protein Interactions (PPIs) have been compiled in a few databases like TIMBAL, 2P2I DB and IPPIDB. Small chemical libraries are used for virtual screening to find novel modulators targeting IL-R binding interface on IL. Molecular dynamic simulations have been further used for disruption mechanism and kinetic studies. IL-2/IL-2R was targeted with clinically tested small molecule modulators like SP4206, and IL-2 levels were known to increase in non-atopic asthma. In the absence of experimentally known modulators against atopic asthma, computational tools are being explored. For example, IL-33 is a target for atopic asthma where IL-33 and its receptor complex structure is available in PDB. In summary, small chemical modulators against ILs are a complementary approach to MAbs and computational tools have been used for identifying these modulators for asthma.

APA, Harvard, Vancouver, ISO, and other styles

26

Ignatova, G. L., E. V. Blinova, and O. L. Minakina. "Clinical efficacy of anti-ige-therapy in adult patients with severe uncontrolled bronchial asthma in real clinical practice." Medical Council, no. 15 (October 12, 2018): 54–58. http://dx.doi.org/10.21518/2079-701x-2018-15-54-58.

Full text

Abstract:

The article presents the results of comprehensive assessment of the efficacy of anti-IgE therapy in adult patients with severe IgE-mediated uncontrolled bronchial asthma in real clinical practice. Omalizumab added to the background anti-inflammatory therapy allowed to reduce the incidence of asthma exacerbations, achieve stable positive dynamics during severe asthma and associated allergic diseases, increase control of the disease, and improve the patients’ quality of life. The drug has a wellcharacterized long-term use safety profile.

APA, Harvard, Vancouver, ISO, and other styles

27

Dhariwal, Jaideep, Michael R. Edwards, and Sebastian L. Johnston. "Anti-viral agents: potential utility in exacerbations of asthma." Current Opinion in Pharmacology 13, no. 3 (June 2013): 331–36. http://dx.doi.org/10.1016/j.coph.2013.04.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Ho, Wanxing Eugene, Yong-Jiang Xu, Fengguo Xu, Chang Cheng, Hong Yong Peh, Shao-Min Huang, Steven R. Tannenbaum, Choon Nam Ong, and W. S. Fred Wong. "Anti-malarial drug artesunate restores metabolic changes in experimental allergic asthma." Metabolomics 11, no. 2 (July 16, 2014): 380–90. http://dx.doi.org/10.1007/s11306-014-0699-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Ponci, Vitor, Rafael C. Silva, Fernanda Paula R. Santana, Simone S. Grecco, Célia Regina M. Fortunato, Maria A. Oliveira, Wothan Tavares-de-Lima, et al. "Biseugenol Exhibited Anti-Inflammatory and Anti-Asthmatic Effects in an Asthma Mouse Model of Mixed-Granulocytic Asthma." Molecules 25, no. 22 (November 18, 2020): 5384. http://dx.doi.org/10.3390/molecules25225384.

Full text

Abstract:

In the present work, the anti-inflammatory and antiasthmatic potential of biseugenol, isolated as the main component from n-hexane extract from leaves of Nectandra leucantha and chemically prepared using oxidative coupling from eugenol, was evaluated in an experimental model of mixed-granulocytic asthma. Initially, in silico studies of biseugenol showed good predictions for drug-likeness, with adherence to Lipinski’s rules of five (RO5), good Absorption, Distribution, Metabolism and Excretion (ADME) properties and no alerts for Pan-Assay Interference Compounds (PAINS), indicating adequate adherence to perform in vivo assays. Biseugenol (20 mg·kg−1) was thus administered intraperitoneally (four days of treatment) and resulted in a significant reduction in both eosinophils and neutrophils of bronchoalveolar lavage fluid in ovalbumin-sensitized mice with no statistical difference from dexamethasone (5 mg·kg−1). As for lung function parameters, biseugenol (20 mg·kg−1) significantly reduced airway and tissue damping in comparison to ovalbumin group, with similar efficacy to positive control dexamethasone. Airway hyperresponsiveness to intravenous methacholine was reduced with biseugenol but was inferior to dexamethasone in higher doses. In conclusion, biseugenol displayed antiasthmatic effects, as observed through the reduction of inflammation and airway hyperresponsiveness, with similar effects to dexamethasone, on mixed-granulocytic ovalbumin-sensitized mice.

APA, Harvard, Vancouver, ISO, and other styles

30

Wang, Alberta L., Ronald Panganiban, Weiliang Qiu, Alvin T. Kho, Geoffrey Chupp, Deborah A. Meyers, Eugene R. Bleecker, Scott T. Weiss, Quan Lu, and Kelan G. Tantisira. "Drug Repurposing to Treat Glucocorticoid Resistance in Asthma." Journal of Personalized Medicine 11, no. 3 (March 3, 2021): 175. http://dx.doi.org/10.3390/jpm11030175.

Full text

Abstract:

Corticosteroid resistance causes significant morbidity in asthma, and drug repurposing may identify timely and cost-effective adjunctive treatments for corticosteroid resistance. In 95 subjects from the Childhood Asthma Management Program (CAMP) and 19 subjects from the Severe Asthma Research Program (SARP), corticosteroid response was measured by the change in percent predicted forced expiratory volume in one second (FEV1). In each cohort, differential gene expression analysis was performed comparing poor (resistant) responders, defined as those with zero to negative change in FEV1, to good responders, followed by Connectivity Map (CMap) analysis to identify inversely associated (i.e., negatively connected) drugs that reversed the gene expression profile of poor responders to resemble that of good responders. Mean connectivity scores weighted by sample size were calculated. The top five drug compound candidates underwent in vitro validation in NF-κB-based luciferase reporter A549 cells stimulated by IL-1β ± dexamethasone. In CAMP and SARP, 134 and 178 respective genes were differentially expressed in poor responders. CMap analysis identified 46 compounds in common across both cohorts with connectivity scores < −50. γ-linolenic acid, ampicillin, exemestane, brinzolamide, and INCA-6 were selected for functional validation. γ-linolenic acid, brinzolamide, and INCA-6 significantly reduced IL-1β induced luciferase activity and potentiated the anti-inflammatory effect of dexamethasone in A549/NF-κB-luc reporter cells. These results demonstrate how existing drugs, including γ-linolenic acid, brinzolamide, and INCA-6, may be repurposed to improve corticosteroid response in asthmatics.

APA, Harvard, Vancouver, ISO, and other styles

31

Douros, Konstantinos, Olympia Sardeli, Spyridon Prountzos, Angeliki Galani, Dafni Moriki, Efthymia Alexopoulou, and Kostas N. Priftis. "Asthma-Like Features and Anti-Asthmatic Drug Prescription in Children with Non-CF Bronchiectasis." Journal of Clinical Medicine 9, no. 12 (December 11, 2020): 4009. http://dx.doi.org/10.3390/jcm9124009.

Full text

Abstract:

Bronchiectasis and asthma may share some characteristics and some patients may have both conditions. The present study aimed to examine the rationale of prophylactic inhaled corticosteroids (ICS) prescription in children with bronchiectasis. Data of children with radiologically established bronchiectasis were retrospectively reviewed. Episodes of dyspnea and wheezing, spirometric indices, total serum IgE, blood eosinophil counts, sensitization to aeroallergens, and air-trapping on expiratory CT scans, were recorded. The study included 65 children 1.5–16 years old, with non-CF bronchiectasis. Episodes of dyspnea or wheezing were reported by 22 (33.8%) and 23 (35.4%), respectively. Skin prick tests to aeroallergens (SPTs) were positive in 15 (23.0%) patients. Mosaic pattern on CT scans was observed in 37 (56.9%) patients. Dyspnea, presence of mosaic pattern, positive reversibility test, and positive SPTs were significantly correlated with the prescription of ICS. The prescription of ICS in children with bronchiectasis is more likely when there are certain asthma-like characteristics. The difficulty to set the diagnosis of real asthma in cases of bronchiectasis may justify the decision of clinicians to start an empirical trial with ICS in certain cases.

APA, Harvard, Vancouver, ISO, and other styles

32

Greenberger, Paul A. "Drug allergy." Allergy and Asthma Proceedings 40, no. 6 (November 1, 2019): 474–79. http://dx.doi.org/10.2500/aap.2019.40.4275.

Full text

Abstract:

Drug allergy describes clinical adverse reactions that are proved or presumed to be immunologically based. Allergic drug reactions do not resemble pharmacologic actions of the incriminated drug and may occur at fractions of what would be the therapeutic dosage. Allergic drug reactions are unpredictable; nevertheless, there is increased risk of drug hypersensitivity in (1) patients with cystic fibrosis who receive antibiotics; (2) patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) who receive trimethoprim-sulfamethoxazole or if human leukocyte antigen (HLA)-B*5701+ and receive the antiretroviral agent abacavir; (3) other genetically susceptible populations, e.g., Han-Chinese with HLA-B*1502+ who develop Stevens-Johnson syndrome and toxic epidermal necrolysis from carbamazepine, with HLA-B*5801+ who are at increased risk for such reactions from allopurinol, those with HLA-A*32:01 and receive vancomycin and develop drug reaction with eosinophilia and systemic symptoms syndrome; and (4) patients with a history of compatible allergic reactions to the same medication, similar class, or potentially unrelated medication. Specific patient groups at higher risk for drug allergy include patients with Epstein-Barr virus infection, chronic lymphatic leukemia, HIV/AIDS, cystic fibrosis, patients with seizures who are being treated with anti-epileptic medications, and patients with asthma (especially severe asthma) who are at increased risk of anaphylaxis from any cause, including drugs, compared with patients without asthma. In patients with a history of penicillin allergy, skin testing helps clarify the current level of risk for anaphylaxis by using the major (penicilloyl polylysine) and minor penicillin determinants in which sensitivity is 99%. If penicilloyl polylysine and penicillin G are used for skin testing, then the sensitivity is approximately 85‐95%. When skin test results are negative, graded challenges are performed to administer optimal or truly essential antibiotics.

APA, Harvard, Vancouver, ISO, and other styles

33

Mishchenko, O. V., V. V. Pavlov, and V. I. Kupaev. "New approach to drug therapy of asthma patients at Samara region." PULMONOLOGIYA, no. 5 (October 28, 2005): 108–13. http://dx.doi.org/10.18093/0869-0189-2005-0-5-108-113.

Full text

Abstract:

The aim of the study was to analyze granted drug provision for asthma (BA) patients at Samara region to spend healthcare resources more rationally and to improve asthma patients' quality of life. This population-based study of drug therapy involved 19,697 BA patients surveyed at Samara region in 2003–2004. The analysis was performed using a personified database of the granted drug provision and integral parameters of health. We used multi-factorial statistical analysis with mathematical modelling. The results demonstrated that the healthcare quality for BA patients depends on a structure of the drug therapy. A model of basic anti-asthmatic therapy for Samara region was created using the study results.

APA, Harvard, Vancouver, ISO, and other styles

34

Pokhaznikova, Marina A. "Tactics of primary care physician in the management of patients with asthma in accordance with the latest changes in international and national guidelines." Russian Family Doctor 23, no. 4 (February 11, 2020): 5–11. http://dx.doi.org/10.17816/rfd18609.

Full text

Abstract:

The article addresses to changes in the management of patients with bronchial asthma in accordance with international and national recommendations of 2019. The new management strategy for patients with mild asthma, the rejection of short-acting 2-agonist (SABA) reliever medication monotherapy in favor of an anti-inflammatory bronchodilator drug will improve disease control, patient compliance, reduce the risk of severe exacerbations and death. The use of the algorithm for diagnosing and management asthma by primary care physicians, developed by experts of the Russian Respiratory Society and the Russian Association of Allergologists and Clinical Immunologists, will reduce the time for diagnosing asthma, timely and correctly prescribe anti-inflammatory therapy and control the course of the disease.

APA, Harvard, Vancouver, ISO, and other styles

35

Morjaria, Jaymin B., Gnanasekaran Gnanakumaran, and Kesavan Suresh Babu. "Anti-IgE in allergic asthma and rhinitis: an update." Expert Opinion on Biological Therapy 7, no. 11 (October 26, 2007): 1739–47. http://dx.doi.org/10.1517/14712598.7.11.1739.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Hamada, Shota, Hironobu Tokumasu, Akira Sato, Masahiro Iwasaku, and Koji Kawakami. "Asthma Controller Medications for Children in Japan." Global Pediatric Health 2 (January 1, 2015): 2333794X1557779. http://dx.doi.org/10.1177/2333794x15577790.

Full text

Abstract:

Background. Treatment and management strategies for asthma in children are generally consistent internationally, but prescription of antiasthma drugs differs among countries. The objective of this study was to examine the prescribing patterns of antiasthma drugs, particularly controller medications, in children. Methods. A retrospective cohort study was performed in children with asthma using an administrative claims database in Japan. Results. A total of 1149 preschool-age and 3226 school-age children were identified. Leukotriene receptor antagonists were prescribed for about 80% of the children. Long-acting β-agonists were prescribed for 87.6% and 59.6% of preschool-age and school-age children, respectively, whereas prescriptions of inhaled corticosteroids had lower rates of 8.2% and 16.5%, respectively. In an examination of prescriptions at 1-month intervals, a relatively high number of children were prescribed bronchodilators without anti-inflammatory agents. Conclusion. Our findings suggest that asthma care for children in Japan can be improved through changes in drug prescriptions.

APA, Harvard, Vancouver, ISO, and other styles

37

Kim, Cheol-Woo, Jae-Hwa Cho, Eun-Hee Jung, and Hye-Kyung Lee. "379 Adverse Drug Reactions to Anti-asthmatics in Patients with Bronchial Asthma." World Allergy Organization Journal 5 (February 2012): S121. http://dx.doi.org/10.1097/01.wox.0000412142.81425.50.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Guvenir, Hakan, Emine Dibek Misirlioglu, Murat Capanoglu, Betul Buyuktiryaki, Zeynep Reyhan Onay, Tayfur Ginis, Muge Toyran, Ersoy Civelek, and Can Naci Kocabas. "The Frequency of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity in Children with Asthma." International Archives of Allergy and Immunology 176, no. 1 (2018): 26–32. http://dx.doi.org/10.1159/000487305.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Ho, Wanxing Eugene, Chang Cheng, Hong Yong Peh, Fengguo Xu, Steven R. Tannenbaum, Choon Nam Ong, and W. S. Fred Wong. "Anti-malarial drug artesunate ameliorates oxidative lung damage in experimental allergic asthma." Free Radical Biology and Medicine 53, no. 3 (August 2012): 498–507. http://dx.doi.org/10.1016/j.freeradbiomed.2012.05.021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Foong, Nathanael Z. E., Anthony C. A. Yii, and Anne A. L. Hsu. "Severe life-threatening asthma precipitated by a topical nonsteroidal anti-inflammatory drug." Annals of Allergy, Asthma & Immunology 120, no. 5 (May 2018): 535–36. http://dx.doi.org/10.1016/j.anai.2017.12.024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Shakirova, D. Kh, and A. Z. Kamaeva. "The modeling of seasonal fluctuations of demand for medications to treat bronchial asthma for the hospitals of the Republic of Tatarstan." Kazan medical journal 94, no. 6 (December 15, 2013): 894–97. http://dx.doi.org/10.17816/kmj1813.

Full text

Abstract:

Aim. To model the seasonal fluctuations of demand for medications to treat bronchial asthma for the hospital use in healthcare facilities of the Republic of Tatarstan. Methods. Statistical methods of absolute and relative differences, seasonality index construction, ABC/XYZ- analysis, modeling of seasonal fluctuations were used for the assessment. Results. By using ABC/XYZ-analysis the estimation of the consumption of certain medications to treat bronchial asthma in hospitals of the Republic of Tatarstan was given. The AX group was the largest share in the total trade (48.27%), but contributed only to 5.88% of the total nomenclature positions number. BX and CX groups, accounting for 0.73% and 0.21% of total consumption respectively, contributed to 1.96% of the nomenclature positions each. 7.84% of assortment positions provided 22.34% of turnover (group AY). Drugs of BY group provided 8.36% of the total sales, and 11.76% of assortment positions, the proportion of CY group (19.61% of items) accounts only for 2.93% of the sales; anti-asthmatic drugs of group Z, the largest by assortment positions number (AZ - 1.96%, BZ - 9.80%, CZ - 39.23%) provided a total of 17.16% of turnover. Assortment positions for modeling the seasonal fluctuations of the demands (AY, BY) were selected. According to the proposed algorithm, the presence of seasonality for each drug was checked. 90 models of seasonal fluctuations were designed and their reliability was tested. The prognosis based on the designed models of demand for medications to treat bronchial asthma for the hospital use in healthcare facilities of the Republic of Tatarstan was given. Conclusion. Assessment of the future demand for anti-asthmatic drugs based on the designed models may allow to optimize the use of funding allocated for the drug provision of patients with bronchial asthma while treated as in-patients.

APA, Harvard, Vancouver, ISO, and other styles

42

Fassakhov, R. S. "SEVERE ASTHMA: PHENOTYPES AND ROLE OF SMALL AIRWAYS." Russian Journal of Allergy 9, no. 6 (December 15, 2012): 49–54. http://dx.doi.org/10.36691/rja713.

Full text

Abstract:

The role of small airways in severe asthma is discussed. The involvement of small airways in the inflammatory process increases the importance of the value delivery systems for effective anti-inflammatory therapy. Extrafine aerosol beclomethasone dipropionate / formoterol (Foster) delivers the drug in the small bronchi significantly improving patient outcomes.

APA, Harvard, Vancouver, ISO, and other styles

43

Du, Yanhui, Jie Luan, Ren Peng Jiang, Juan Liu, and Yan Ma. "Myrcene exerts anti-asthmatic activity in neonatal rats via modulating the matrix remodeling." International Journal of Immunopathology and Pharmacology 34 (January 2020): 205873842095494. http://dx.doi.org/10.1177/2058738420954948.

Full text

Abstract:

Myrcene (MC), an organic hydrocarbon, was found to exert anti-inflammatory, analgesic, antimutagenic and antioxidant properties. However, the protective role of MC has not been reported against neonatal asthma. Wistar rats induced with asthma were administered with MC; while asthma control and vehicle control were maintained without MC administration. At the end of the experimental period, lung histology, inflammatory cell counts, cytokine analysis, matrix protein expressions were elucidated. Rats administered with MC exerted significant ( P < 0.05) defense in protecting the lung tissue with the evidenced restoration of alveolar thickening of the lung tissues. Also, the present study elicited the anti-asthmatic activity of MC, especially via modulating the extracellular matrix protein expression in the asthma-induced animals, while a significant reduction ( P < 0.05) in the fibrotic markers were found in MC treated animals. Moreover, the protective effect of MC was evidenced with reduced leukocyte infiltration in BALF, hypersensitive specific IgE levels with a profound decrease in the inflammatory cytokines such as IL-2, IL-4, IL-18, and IL-21 in MC administered animals compared to the asthma-induced group. To an extent, the markers of asthmatic inflammation such as CD14, MCP-1, and TARC were also found to be attenuated in MC exposed animals. The possible application of MC is a promising drug for the treatment of asthma-mediated complications.

APA, Harvard, Vancouver, ISO, and other styles

44

Satkunam, Natasha, Zaeem A. Siddiqi, and Dilini Vethanayagam. "Severe Asthma Associated with Myasthenia Gravis." Canadian Respiratory Journal 21, no. 1 (2014): e1-e3. http://dx.doi.org/10.1155/2014/914719.

Full text

Abstract:

Severe asthma constitutes a subgroup of approximately 10% of all asthma cases. Approximately one-half of these individuals have a refractory form of the disease in which atopy and T-helper cell 2-skewed immunological response may not be as closely linked to the disease as in other phenotypes of asthma. This suggests that not all asthma is explained by a T-helper cell 2-skewed immunological response, and that other immunological mechanisms may be important in this category of nonatopic asthma. The authors present a case involving a 55-year-old Caucasian man with nonatopic, adult-onset asthma, nonsteroidal anti-inflammatory drug sensitivity and idiopathic urticaria. This individual presented two years following his initial asthma diagnosis with diplopia and mild ptosis, and was subsequently diagnosed with seropositive myasthenia gravis.

APA, Harvard, Vancouver, ISO, and other styles

45

Costa, Paula Priscila Correia, Stefanie Bressan Waller, Gilvan Ribeiro dos Santos, Fladimir de Lima Gondim, Daniel Silveira Serra, Francisco Sales Ávila Cavalcante, Florêncio Sousa Gouveia Júnior, et al. "Anti-asthmatic effect of nitric oxide metallo-donor FOR811A [cis-[Ru(bpy)2(2-MIM)(NO)](PF6)3] in the respiratory mechanics of Swiss mice." PLOS ONE 16, no. 3 (March 12, 2021): e0248394. http://dx.doi.org/10.1371/journal.pone.0248394.

Full text

Abstract:

We aimed at evaluating the anti-asthmatic effect of cis-[Ru(bpy)2(2-MIM)(NO)](PF6)3 (FOR811A), a nitrosyl-ruthenium compound, in a murine model of allergic asthma. The anti-asthmatic effects were analyzed by measuring the mechanical lung and morphometrical parameters in female Swiss mice allocated in the following groups: untreated control (Ctl+Sal) and control treated with FOR811A (Ctl+FOR), along asthmatic groups untreated (Ast+Sal) and treated with FOR811A (Ast+FOR). The drug-protein interaction was evaluated by in-silico assay using molecular docking. The results showed that the use of FOR811A in experimental asthma (Ast+FOR) decreased the pressure-volume curve, hysteresis, tissue elastance, tissue resistance, and airway resistance, similar to the control groups (Ctl+Sal; Ctl+FOR). However, it differed from the untreated asthmatic group (Ast+Sal, p<0.05), indicating that FOR811A corrected the lung parenchyma and relaxed the smooth muscles of the bronchi. Similar to control groups (Ctl+Sal; Ctl+FOR), FOR811A increased the inspiratory capacity and static compliance in asthmatic animals (Ast+Sal, p<0.05), showing that this metallodrug improved the capacity of inspiration during asthma. The morphometric parameters showed that FOR811A decreased the alveolar collapse and kept the bronchoconstriction during asthma. Beyond that, the molecular docking using FOR811A showed a strong interaction in the distal portion of the heme group of the soluble guanylate cyclase, particularly with cysteine residue (Cys141). In summary, FOR811A relaxed bronchial smooth muscles and improved respiratory mechanics during asthma, providing a protective effect and promising use for the development of an anti-asthmatic drug.

APA, Harvard, Vancouver, ISO, and other styles

46

Riccioni, Graziano, Barbara Mancini, Tonino Bucciarelli, Carmine di Ilio, and Nicolantonio D’Orazio. "Role of anti-oxidants in the treatment of bronchial asthma." Drug Discovery Today: Therapeutic Strategies 3, no. 3 (September 2006): 293–98. http://dx.doi.org/10.1016/j.ddstr.2006.09.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Yamashita, Masamichi. "PPARα/γ-Independent Effects of PPARα/γLigands on Cysteinyl Leukotriene Production in Mast Cells." PPAR Research 2008 (2008): 1–6. http://dx.doi.org/10.1155/2008/293538.

Full text

Abstract:

Peroxisome proliferator-activated receptor (PPAR)αligands (Wy-14,643, and fenofibrate) and PPARγligands (troglitazone and ciglitazone) inhibit antigen-induced cysteinyl leukotriene production in immunoglobulin E-treated mast cells. The inhibitory effect of these ligands on cysteinyl leukotriene production is quite strong and is almost equivalent to that of the anti-asthma compound zileuton. To develop new aspects for anti-asthma drugs the pharmacological target of these compounds should be clarified. Experiments with bone-marrow-derived mast cells from PPARαknockout mice and pharmacological inhibitors of PPARγsuggest that the inhibitory effects of these ligands are independent of PPARsαandγ. The mechanisms of the PPAR-independent inhibition by these agents on cysteinyl leukotriene production are discussed in this review.

APA, Harvard, Vancouver, ISO, and other styles

48

Han, Jong-Heon, Kyuhee Park, Jong Lee, Yeon-Ju Nam, Jungeun Yang, Myung-Jin Song, Sung-Jin Ko, et al. "Anti-inflammatory Effects of Distylium racemosum Extract in a Mouse Model of Allergic Asthma." Planta Medica International Open 5, no. 02 (April 2018): e48-e54. http://dx.doi.org/10.1055/a-0600-9786.

Full text

Abstract:

AbstractAllergic asthma is a complex disorder characterized by chronic airway inflammation. Patients with asthma often show poor adherence to corticosteroid therapy owing to prominent side effects, which provides a rationale to explore new drug classes with a better safety profile. In this study, we sought to discover natural products that inhibit the activity of phosphodiesterase 4, which is considered a potential molecular target for anti-inflammatory therapy. The screening of a plant extract library led to the identification of Distylium racemosum, which inhibited phosphodiesterase 4 activity in vitro and suppressed lipopolysaccharide-induced inflammatory signaling in cultured cells. In a mouse model of ovalbumin-induced allergic asthma, D. racemosum treatment significantly reduced inflammatory responses in the lung, as well as serum immunoglobulin E levels. Although the active constituents of D. racemosum extract and the exact mechanism underlying the in vivo action of D. racemosum remain to be elucidated, our results provide a basis for further investigation of D. racemosum extract as a novel anti-inflammatory agent for allergic asthma.

APA, Harvard, Vancouver, ISO, and other styles

49

A, Muthukumar, and Sundara Ganapathy R. "A STUDY ON ADVERSE DRUG REACTIONS AND THEIR RISK FACTORS OF ANTI- ASTHMATIC AGENTS AMONG GARMENTS DUST-INDUCED ASTHMATIC PATIENTS IN MANCHESTER OF SOUTH INDIA." Asian Journal of Pharmaceutical and Clinical Research 11, no. 9 (September 7, 2018): 130. http://dx.doi.org/10.22159/ajpcr.2018.v11i9.25561.

Full text

Abstract:

Objective: Adverse drug reactions (ADRs) are well known to occur with any class of drugs when used in normal doses for the management of diseases. The main aim of the study was to detect and analyze ADRs in patients with bronchial asthma in a Coimbatore zone.Methods: This was an observational, voluntary reporting study. The study was conducted in and around Coimbatore. Samples are collected in all age groups. We are taken support of “Suspected ADR” reporting form from Indian pharmacopoeia commission to collect samples.Results: A total of 1163 ADRs were reported by patients during the study period with male predominance over female. The average age of the patients in the study was found to be 30–60 years. The majority of ADR occurred in the age group 30–60 years, the average duration of bronchial asthma in this study was found to be 3 years. The most commonly occurred ADRs were beclomethasane-induced seizures, salbutamol-induced tremor, anorexia, and nausea, and nausea, salmeterol-induced tremor, and montelukast-induced angioedema were also common.Conclusion: An ADR due to oral anti-asthmatic is a frequent problem. Few multicenter studies are needed for a strong anti-asthmatic drug ADRs database in India.

APA, Harvard, Vancouver, ISO, and other styles

50

Chang, Tse-Wen. "S2g1-4 A rational approach for designing an antibody drug : anti-IgE for treating asthma and allergic diseases(S2-g1: "Drug Development",Symposia,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S126. http://dx.doi.org/10.2142/biophys.46.s126_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Anti asthma drug'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles